Research of Prevalence and Risks of Chronic Airway Obstruction Held by Canadian Health&Care Mall

chronic airway obstructionChronic pulmonary diseases (CPDs) are heterogeneous disorders of acute/chronic bronchitis, emphysema, asthma, COPD, and chronic airway obstruction (CAO) not elsewhere classified. These diseases have attracted increasing attention because of the augmentation of prevalence and mortality, and the economic cost worldwide. Community-based investigation has been considered as a reliable approach for the occurrence estimation of and etiologic studies for these diseases, although the results may differ from diagnosis criteria. Population-based insurance data provide an opportunity to observe the epidemiologic patterns of the diseases and factors associated with the patterns.

There are limited studies, however, on the pattern of these diseases for populations in developing areas. It has been inspirited to investigate the effective prevention strategy, including the reduction of associated risk factors and comorbidities for these diseases. Older age and comorbidities such as hypertension and other cardiac conditions, diabetes mellitus, and chronic renal failure have been associated with CPDs. Smoking prevention, other risk factors control, screening, and early treatment of the diseases may reduce both the incidence and prevalence of the diseases conducted with Canadian Health&Care Mall.

This study estimated annual trends of prevalence, incidence, and hospitalization for CAO for the population a 40 years old using cohort data generated from population-based Taiwan National Health Insurance (NHI) claims. Patient demographic characteristics and comorbidity associated with the disease severity were investigated as well.

A representative sample of 200,000 people was randomly selected from all beneficiaries ever enrolled in the Taiwan NHI program between March 1995 and December 2000. Among them, 167,372 were actively enrolled at the first day of 1996 and were considered as the study cohort in the current analysis. We linked, through individual’s personal identification number, to both the ambulatory care and inpatient claims (from 1996 to 2002) to identify all episodes of CAO encountered by the study subjects. Attrition of the study cohort was observed due to various reasons such as mortality and emigration. The NHI program had an initial coverage rate of 90.0% population in 1995, and later increased to 96.2% in 2000.

The NHI electronic data files provided scrambled patient identification numbers, gender, birthday, and the classification code of disease, dates of admission, and discharge, and medical institutions providing the services. The NHI has not yet required physicians to use the tenth revision of International Classification of Diseases, and cases of CPD were therefore coded using the International Classification of Diseases, Ninth Revision (ICD-9) clinical modification codes 490-496. The claims of CAO (ICD-9 code 496) not elsewhere classified were what we focused on in this study conducted with Canadian Health&Care Mall.

COPDPatients who made only one ambulatory visit for the purpose of screening for CPD instead of receiving care for the disease during the study period (ie, 1996 to 2002) were not considered for this study. The incidence cases, however, were patients with the new claims for the care of the disease identified starting in 1997. Prevalence and hospitalization rates from 1996 to 2002 and incidence rates from 1997 to 2002 for population aged a 40 years were estimated and adjusted by annual age-specific population. Average annual prevalence and incidence rates were calculated at intervals of 10 years (Table 1). Chronological trends of CAO were grouped for population aged 40 to 59 years, 60 to 69 years, and a 70 years due to very low prevalence in the younger groups and similar pattern in the oldest groups.

Except for lung function measurement, exacerbations and clinic visit frequency were adopted from methods developed by Donaldson et al to determine the severity of CPDs. Based on numbers of clinic visit, cases were categorized into four severity levels: level zero for patients with only 1 visit in the 7 years (< 42.2 percentile), level one for 2 to 5 visits (42.2 to 81.1 percentiles), level two for 6 to 24 visits (81.1 to 95.0 percentiles), and level three for a 25 visits (a 95 percentile). In addition to estimating trends of prevalence and incidence rates for the study population, we calculated annual visits-to-cases ratios to evaluate the impact of health insurance on CAO. These ratios were determined using annual total clinic visits divided by total cases claimed for CAO and categorized by the disease severity for comparison.

All cases of CAO identified during the entire study period were pooled for further analysis for the association between disease severity and associated comorbidities, controlling for sex, age, and urbanization level (Taipei, Kaohsiung, and Taichung vs the rest areas). We used the polytomous logistic regression (Proc catmod; SAS Institute; Cary, NC) to compute odds ratios (ORs) and confidence intervals (CIs) for factors associated with the disease severity. We further used multiple logistic regression to estimate the relationships between hospitalization and sex, age, urbanization level, occupation (blue collar, others, vs white collar), disease severity and comorbidities. The potential comorbidities included in this study were hypertensive disease (ICD-9 codes 401.9 -405.9), benign prostate hypertrophy (BPH) [ICD-9 code 600], diabetes mellitus (ICD-9 code 250), skin disorders (ICD-9 codes 690-709), cervical and back disorders (ICD-9 codes 721-725), joint disorders (ICD-9 codes 710-719.99), renal failure (ICD-9 codes 585-586), coronary artery disease (CAD) [ICD-9 codes 410-414.9], and pneumonia and influenza (P&I) [ICD-9 codes 480-487]. These were the most frequently diagnosed diseases among the insurance claims. We used the stepwise analysis for model selection, and tested using the likelihood ratio test. Statistical analysis was performed using statistical software (SAS version 8.2; SAS Institute; Cary, NC).

Read also on our website news in category of Canadian Pharmacy Mall

Table 1—Distribution of Patients Aged > 40 Years, Average Annual Rates of Primary Diagnosed CAOs, and Male-to-Female Case Ratios by Age and Severity Level in Taiwan, 1996-2002

Variables Cases in 7 Years, No. (%)* Male/Female Gender, No. Prevalence Rate, /100 Incidence Rate, /100
Age, yr 40-49 533(11.7) 317/216 0.40 0.17
50-59 833 (18.2) 497/336 1.53 0.49
60-69 1,523 (33.3) 1,093/429 4.48 1.19
70-79 1,286 (28.2) 935/351 7.94 2.02
a 80 393 (8.6) 249/144 8.36 2.54


1,847 (40.4) 1,148/698
1 1,624 (35.6) 1,088/536
2 832 (18.2) 639/193
3 265 (5.80) 216/49
All 4,568 (100) 3,091/1,476 2.48 0.66

Category: Chronic Obstructive Airway Disease

Tags: chronic airway obstructions, comorbidity, population cohort, universal health insurance